Geographic variation of mutagenic exposures in kidney cancer genomes 1

2

3	Sergey Senkin ¹ , Sarah Moody ² , Marcos Díaz-Gay ^{3,4,5} , Behnoush Abedi-Ardekani ¹ , Thomas
4	Cattiaux ¹ , Aida Ferreiro-Iglesias ¹ , Jingwei Wang ² , Stephen Fitzgerald ² , Mariya
5	Kazachkova ^{3,6,5} , Raviteja Vangara ^{3,4,5} , Anh Phuong Le ² , Erik N. Bergstrom ^{3,4,5} , Azhar
6	Khandekar ^{3,4,5} , Burçak Otlu ^{3,4,5,7} , Saamin Cheema ² , Calli Latimer ² , Emily Thomas ² , Joshua
7	Ronald Atkins ⁸ , Karl Smith-Byrne ⁸ , Ricardo Cortez Cardoso Penha ¹ , Christine Carreira ⁹ ,
8	Priscilia Chopard ¹ , Valérie Gaborieau ¹ , Pekka Keski-Rahkonen ¹⁰ , David Jones ² , Jon W.
9	Teague ² , Sophie Ferlicot ¹¹ , Mojgan Asgari ¹² , Surasak Sangkhathat ¹³ , Worapat
10	Attawettayanon ¹⁴ , Beata Świątkowska ¹⁵ , Sonata Jarmalaite ^{16,17} , Rasa Sabaliauskaite ¹⁶ ,
11	Tatsuhiro Shibata ^{18,19} , Akihiko Fukagawa ^{19,20} , Dana Mates ²¹ , Viorel Jinga ²² , Stefan Rascu ²² ,
12	Mirjana Mijuskovic ²³ , Slavisa Savic ²⁴ , Sasa Milosavljevic ²⁵ , John M.S. Bartlett ²⁶ , Monique
13	Albert ^{27,28} , Larry Phouthavongsy ²⁸ , Patricia Ashton-Prolla ^{29,30} , Mariana R. Botton ³¹ , Brasil
14	Silva Neto ^{32,33} , Stephania Martins Bezerra ³⁴ , Maria Paula Curado ³⁵ , Stênio de Cássio
15	Zequi ^{36,37,38,39} , Rui Manuel Reis ^{40,41} , Eliney Faria ⁴² , Nei Soares Menezes ⁴³ , Renata Spagnoli
16	Ferrari ⁴² , Rosamonde E. Banks ⁴⁴ , Naveen S. Vasudev ⁴⁴ , David Zaridze ⁴⁵ , Anush Mukeriya ⁴⁵ ,
17	Oxana Shangina ⁴⁵ , Vsevolod Matveev ⁴⁶ , Lenka Foretova ⁴⁷ , Marie Navratilova ⁴⁷ , Ivana
18	Holcatova ^{48,49} , Anna Hornakova ⁵⁰ , Vladimir Janout ⁵¹ , Mark Purdue ⁵² , Nathaniel Rothman ⁵² ,
19	Stephen J. Chanock ⁵² , Per Magne Ueland ⁵³ , Mattias Johansson ¹ , James McKay ¹ , Ghislaine
20	Scelo ⁵⁴ , Estelle Chanudet ⁵⁵ , Laura Humphreys ² , Ana Carolina de Carvalho ¹ , Sandra
21	Perdomo ¹ , Ludmil B. Alexandrov ^{3,4,5} , Michael R. Stratton ² , Paul Brennan ^{1*}
22	
23	¹ Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO),

Lyon, France, ²Cancer, Ageing and Somatic Mutation, Wellcome Sanger Institute, 24

25 Cambridge, UK, ³Department of Cellular and Molecular Medicine, University of California

- 26 San Diego, La Jolla, USA, ⁴Department of Bioengineering, University of California San
- Diego, La Jolla, USA, ⁵Moores Cancer Center, University of California San Diego, La Jolla, 27 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

USA, ⁶Biomedical Sciences Graduate Program, University of California San Diego, La Jolla, 28 29 USA, ⁷Department of Health Informatics, Graduate School of Informatics, Middle East 30 Technical University, Ankara, Turkey, ⁸Cancer Epidemiology Unit, The Nuffield Department of Population Health, University of Oxford, Oxford, UK, ⁹Evidence Synthesis and 31 Classification Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, 32 France, ¹⁰Nutrition and Metabolism Branch, International Agency for Research on Cancer 33 (IARC/WHO), Lyon, France, ¹¹Service d'Anatomie Pathologique, Assistance Publique-34 Hôpitaux de Paris, Univeristé Paris-Saclay, Le Kremlin-Bicêtre, France, ¹²Oncopathology 35 Research Center, Iran University of Medical Sciences, Tehran, Iran, ¹³Translational Medicine 36 Research Center, Faculty of Medicine, Prince of Songkla University, Hat Yai, 37 38 Thailand, ¹⁴Department of Surgery, Urology, Faculty of Medicine, Prince of Songkla 39 University, Hat Yai, Thailand, ¹⁵Department of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Łódź, Poland, ¹⁶Laboratory of Genetic Diagnostic, National Cancer 40 Institute, Vilnius, Lithuania, ¹⁷Department of Botany and Genetics, Institute of Biosciences, 41 42 Vilnius University, Vilnius, Lithuania, ¹⁸Laboratory of Molecular Medicine, The Institute of Medical Science, The University of Tokyo, Minato-ku, Japan, ¹⁹Division of Cancer Genomics, 43 National Cancer Center Research Institute, Chuo-ku, Japan, ²⁰Department of Pathology, 44 Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan, ²¹Occupational 45 Health and Toxicology, National Center for Environmental Risk Monitoring, National Institute 46 of Public Health, Bucharest, Romania, ²²Urology Department, "Carol Davila" University of 47 Medicine and Pharmacy - "Prof. Dr. Th. Burghele" Clinical Hospital, Bucharest, 48 Romania, ²³Clinic of Nefrology, Faculty of Medicine, Military Medical Academy, Belgrade, 49 50 Serbia, ²⁴Department of Urology, University Hospital "Dr D. Misovic" Clinical Center, Belgrade, Serbia, ²⁵International Organization for Cancer Prevention and Research, 51 Belgrade, Serbia, ²⁶Cancer Research UK Edinburgh Centre, Institute of Genetics and 52 Cancer, University of Edinburgh, Edinburgh, Scotland, ²⁷Centre for Biodiversity Genomics, 53 54 University of Guelph, Guelph, Canada, ²⁸Ontario Tumour Bank, Ontario Institute for Cancer Research, Toronto, Canada, ²⁹Experimental Research Center, Genomic Medicine 55

Laboratory, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ³⁰Post-Graduate 56 Program in Genetics and Molecular Biology, Universidade Federal do Rio Grande do Sul, 57 Porto Alegre, Brazil, ³¹Diagnostic Laboratory Service, Personalized Medicine, Hospital de 58 Clínicas de Porto Alegre, Porto Alegre, Brazil, ³²Service of Urology, Hospital de Clínicas de 59 Porto Alegre, Porto Alegre, Brazil, ³³Post-Graduate Program in Medicine: Surgical Sciences, 60 Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ³⁴Department of Anatomic 61 Pathology, A.C. Camargo Cancer Center, São Paulo, Brazil, ³⁵Department of Epidemiology, 62 A.C. Camargo Cancer Center, São Paulo, Brazil, ³⁶Department of Urology, A.C. Camargo 63 Cancer Center, São Paulo, Brazil, ³⁷National Institute for Science and Technology in 64 Oncogenomics and Therapeutic Innovation, A.C. Camargo Cancer Center, São Paulo, 65 Brazil, ³⁸Latin American Renal Cancer Group – LARCG, São Paulo, Brazil, ³⁹Department of 66 Surgery, Division of Urology, Sao Paulo Federal University - UNIFESP, São Paulo, 67 Brazil, ⁴⁰Molecular Oncology Research Center, Barretos Cancer Hospital, Brazil, ⁴¹Life and 68 Health Sciences Research Institute (ICVS), School of Medicine, Minho University, Braga, 69 70 Portugal, ⁴²Department of Urology, Barretos Cancer Hospital, Brazil, ⁴³Department of Pathology, Barretos Cancer Hospital, Brazil, ⁴⁴Leeds Institute of Medical Research at St 71 James's, University of Leeds, Leeds, UK, ⁴⁵Clinical Epidemiology, N.N.Blokhin National 72 Medical Research Centre of Oncology, Moscow, Russia, ⁴⁶Department of Urology, 73 N.N.Blokhin National Medical Research Centre of Oncology, Moscow, Russia, ⁴⁷Department 74 75 of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic, ⁴⁸Institute of Public Health & Preventive Medicine, 2nd Faculty of Medicine, 76 Charles University, Prague, Czech Republic, ⁴⁹Department of Oncology, 2nd Faculty of 77 78 Medicine, Charles University and Motol University Hospital, Prague, Czech Republic, ⁵⁰Institute of Hygiene & Epidemiology, 1nd Faculty of Medicine, Charles University, 79 Prague, Czech Republic, ⁵¹Faculty of Health Sciences, Palacky University, Olomouc, Czech 80 Republic, ⁵²Division of Cancer Epidemiology and Genetics, National Cancer Institute, 81 Rockville, USA, ⁵³Bevital AS, Bergen, Norway, ⁵⁴Observational & Pragmatic Research 82

- 83 Institute Pte Ltd, Singapore, Singapore, ⁵⁵Department of Pathology, Radboud University
- 84 Medical Centre, Nijmegen, Netherlands
- 85 These authors contributed equally: Sergey Senkin, Sarah Moody
- 86 * Corresponding author: Paul Brennan
- 87

88 ABSTRACT

89 International differences in the incidence of many cancer types indicate the existence of 90 carcinogen exposures that have not been identified by conventional epidemiology yet potentially make a substantial contribution to cancer burden¹. This pertains to clear cell renal 91 cell carcinoma (ccRCC), for which obesity, hypertension, and tobacco smoking are risk factors 92 but do not explain its geographical variation in incidence². Some carcinogens generate somatic 93 94 mutations and a complementary strategy for detecting past exposures is to sequence the genomes of cancers from populations with different incidence rates and infer underlying 95 96 causes from differences in patterns of somatic mutations. Here, we sequenced 962 ccRCC 97 from 11 countries of varying incidence. Somatic mutation profiles differed between countries. 98 In Romania, Serbia and Thailand, mutational signatures likely caused by extracts of 99 Aristolochia plants were present in most cases and rare elsewhere. In Japan, a mutational 100 signature of unknown cause was found in >70% cases and <2% elsewhere. A further 101 mutational signature of unknown cause was ubiquitous but exhibited higher mutation loads in 102 countries with higher kidney cancer incidence rates (p-value $<6 \times 10^{-18}$). Known signatures of 103 tobacco smoking correlated with tobacco consumption, but no signature was associated with 104 obesity or hypertension suggesting non-mutagenic mechanisms of action underlying these risk 105 factors. The results indicate the existence of multiple, geographically variable, mutagenic 106 exposures potentially affecting 10s of millions of people and illustrate the opportunities for new 107 insights into cancer causation through large-scale global cancer genomics.

108

109

110 INTRODUCTION

The incidence rates of most adult cancers vary substantially between geographical regions and many such differences are unexplained by known risk factors¹. Together with unexplained trends in incidence over time, this indicates the likely presence of unknown environmental or lifestyle causes for many cancer types¹. Traditional epidemiological studies have identified many important lifestyle, environmental and infectious risk factors for cancer. However, they have had limited success in recent decades suggesting that alternative study designs are required if further risk factors are to be identified.

118

Characterization of mutational signatures within cancer genomes³ is an approach 119 120 complementary to conventional epidemiology for investigating unknown causes of cancer. 121 Most cancers contain thousands of somatic mutations that have occurred over the lifetime of 122 the individual. These can be caused by endogenous cellular processes, such as imperfect 123 DNA replication and repair, or by exposure to exogenous environmental or lifestyle mutagens 124 such as ultraviolet radiation in sunlight and compounds in cigarette smoke. Mutational 125 signatures are the patterns of somatic mutation imprinted on genomes by individual mutational processes. Analysis of thousands of cancer genome sequences from most cancer types has 126 127 established a set of reference mutational signatures including 71 single base substitution 128 (SBS) or doublet base substitution (DBS) signatures, and 18 small insertion and deletion (ID) 129 signatures⁴. A possible etiology has been suggested for 47 SBS/DBS signatures and nine ID 130 signatures.

131

Kidney cancer has particularly high incidence rates in Central and Northern Europe, notably in the Czech Republic and Lithuania, and has shown increasing incidence in high income countries in recent decades (**Fig. 1**)². Most kidney cancers are clear cell renal cell carcinomas (ccRCC)³ for which obesity, hypertension and tobacco smoking are known risk factors². However, these account for <50% of the global ccRCC burden and do not explain geographical or temporal incidence trends. Previous ccRCC genome sequencing studies have included relatively modest numbers of individuals from a small number of countries with limited variation in ccRCC incidence⁵⁻⁹ and have not comprehensively examined associations between ccRCC risk factors and mutational signatures. To detect the activity of unknown carcinogens involved in ccRCC development and to investigate the mechanisms of action of known risk factors, we generated and analyzed epidemiological and whole genome sequencing data from a large international series of ccRCC¹⁰.

144

145 **RESULTS**

146 A total of 962 ccRCC cases from 11 countries in four continents were studied, including Czech 147 Republic (n=259), Russia (n=216), United Kingdom (n=115), Brazil (n=96), Canada (n=73), 148 Serbia (n=69), Romania (n=64), Japan (n=36), Lithuania (n=16), Poland (n=13), and Thailand 149 (*n*=5; Fig. 1; Table 1; Methods). These encompass a broad range of ccRCC incidence, from the highest global age-standardized rates (ASRs) of Lithuania and Czech Republic (ASRs of 150 151 14.5 and 14.4/100,000 respectively) to the relatively low rates of Brazil and Thailand (ASRs of 4.5 and 1.8/100,000 respectively)¹¹. Epidemiological guestionnaire data were available on sex, 152 153 age at diagnosis, and important risk factors including body mass index (BMI), hypertension, and tobacco smoking (Table 1, Supplementary Table 1). DNAs from ccRCCs and blood from 154 155 the same individuals were extracted and whole genome sequenced to average coverage of 156 54-fold and 31-fold, respectively.

157

Somatic mutation burdens in the 962 ccRCC genomes ranged from 803 to 45,376 (median 5,093) for single base substitutions (SBS), 2 to 240 (median 53) for doublet base substitutions (DBS), and 10 to 14,770 (median 695) for small insertions and deletions (**Supplementary Table 2**). The average burden of all three mutation types differed between the 11 countries (pvalue $<2 \times 10^{-23}$, p-value $<2 \times 10^{-14}$, p-value $<6 \times 10^{-14}$, for SBSs, DBSs, and IDs, respectively). In particular, the burden of all mutation types was elevated in Romania compared to other countries (**Extended Data Fig. 1**). Principal Component Analysis (PCA) performed on the

proportions of the six primary SBS mutation classes (C>A, C>G, C>T, T>A, T>C, T>G) in each
sample identified a distinct cluster of mainly Romanian and Serbian cases and a further cluster
of mainly Japanese cases (Extended Data Fig. 2). The results, therefore, clearly demonstrate
geographical variation of somatic mutation loads and patterns in ccRCC.

169

170 To investigate the mutational processes contributing to the geographical variation in mutation 171 burdens we extracted mutational signatures and estimated the contribution of each signature 172 to each ccRCC genome (Supplementary Tables 3-7). Ten signatures with strong similarity to 173 a reference signature in the Catalogue of Somatic Mutations in Cancer (COSMIC) database were extracted: SBS1, due to deamination of 5-methylcytosine¹²; SBS2 and SBS13, due to 174 175 cytosine deamination by Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) DNA editing enzymes¹²; SBS4, due to tobacco smoke mutagens¹³; SBS5, due to 176 an endogenous mutational process in which mutations accumulate with age¹³; SBS12, of 177 unknown cause; SBS18, due to DNA damage by reactive oxygen species¹³; SBS21 and 178 SBS44, due to defective DNA mismatch repair^{13,14}; and SBS22, due to Aristolochic acid 179 exposure^{15,16}. 180

181

182 Five further SBS signatures were identified which were not well described by the COSMIC 183 catalogue (Fig. 2; Supplementary Table 8). SBS40a, SBS40b and SBS40c were present in 184 most ccRCC, accounting for, on average, ~30%, ~20%, and ~3% of mutations respectively 185 (Fig. 2b). Combined, they closely resemble the previously reported SBS40 (0.96 cosine 186 similarity), suggesting that the large number of ccRCC whole genomes analyzed here provides 187 the power to separate the constituent component signatures of SBS40. SBS40 was previously 188 reported frequently, and at high levels, in kidney cancer, but also in other cancers, and is of 189 unknown etiology. Like the composite SBS40, SBS40a is present in multiple cancer types. 190 However, SBS40b and SBS40c are largely restricted to ccRCC (Supplementary Note, 191 Extended Data Fig. 3). SBS H was found in a single case and SBS I is related to Aristolochic 192 acid exposure (see below; SBS I has been renamed as SBS22b). Analysis of all other types

193 of mutational signatures, including doublet bases substitutions, small insertion and deletions,

194 copy number variants and structural variants, is presented in Supplementary results.

195

196 The mutation burdens of multiple SBS mutational signatures varied between the 11 countries. 197 SBS22 is thought to be caused by Aristolochic acids, mutagenic derivatives of plants of the 198 Aristolochia genus which are carcinogenic and also cause Balkan endemic nephropathy 199 (BEN), a kidney disease prevalent in areas adjacent to the Danube in Southeastern Europe¹⁷. 200 SBS22 has previously been found in ccRCC, other urothelial tract cancers, and hepatocellular carcinomas from Romania^{5,18} and various countries in East and South-East Asia^{15,16,19}. In this 201 202 study, SBS22 was present in high proportions of ccRCC from Romania (45/64, 70%), Serbia 203 (16/69, 23%), and Thailand (3/5, 60%), often with very high mutation burdens. Of note, given 204 the limited number of cases in Thailand, they may not be representative of ccRCC in that 205 region. The presence of SBS22 was strongly correlated with that of new signatures SBS I, 206 DBS D, and ID C (Extended Data Fig. 4-6) which are, therefore, also probably due to 207 Aristolochic acid exposure. SBS 1, like SBS22, is composed predominantly of T>A mutations. 208 The signature identified previously as SBS22, has therefore been renamed SBS22a, and 209 SBS I has been named SBS22b. The mutation burden of both SBS22a and SBS22b differed 210 between Serbia and Romania, with higher levels being detected in Romania, and away from 211 recognized BEN zones (Fig 3a-c). The two signatures may be due to different subsets of 212 Aristolochic acids, and/or to different metabolites, which induce slightly different mutational 213 patterns. Only five ccRCC cases were known to reside within recognized BEN zones, 214 suggesting no clear link between the two diseases. While the source of this exposure is 215 uncertain, these results indicate that a substantial proportion of the population over a wide geographical area of Eastern Europe, possibly numbering in the 10s of millions, has been 216 217 exposed to Aristolochic acid containing compounds, the public health consequences of which 218 are uncertain.

219

220 SBS12 was present in 72% of Japanese and 2% of non-Japanese ccRCC (pvalue= 4.7×10^{-78}) (**Extended Data Fig. 7h**). Compared to the mutation burdens imposed by 221 222 Aristolochic acid in ccRCC, SBS12 contributed modest mutation loads. SBS12 is composed 223 predominantly of T>C substitutions and exhibits strong transcriptional strand bias with more T>C mutations on the transcribed than untranscribed strands of protein coding genes. 224 225 Transcriptional strand bias is typically caused by activity of transcription-coupled nucleotide 226 excision repair acting on bulky DNA adducts due to exogenous mutagenic exposures such as tobacco smoke chemicals¹³, ultraviolet light¹³, Aristolochic acids¹⁵, and aflatoxins²⁰. Assuming 227 228 that transcription-coupled repair of DNA adducts is responsible for the SBS12 strand bias, the 229 adducts are likely on adenine. Alternatively, transcriptional strand bias can also be caused by 230 transcription-coupled damage^{21,22}. The presence of SBS12 was replicated in two further series 231 of whole genome sequenced ccRCC from Japan including 14 cases from an independent 232 study group who undertook a broad genomic analysis of ccRCC but without detailed mutational signature analysis²³, and a more recent unpublished series of 61 cases from an additional 233 234 cohort of ccRCC sequenced by the same center as the initial cohort (Supplementary Note). SBS12 was present in 12/14 cases (85%) cases and 46/61 (75%) of cases, respectively. 235 SBS12 was previously reported in hepatocellular carcinomas^{4,13} and additional analysis of 236 237 existing datasets revealed strong SBS12 enrichment in hepatocellular carcinomas from Japan compared to other countries (p-value= 3.8×10^{-15} ; **Supplementary Note**). These results, 238 239 therefore, indicate that exposure to an agent contributing SBS12 mutations to kidney and liver 240 cancer is common in Japan and rare in the other 10 countries included in this study. The agent 241 responsible for SBS12 is unknown although the precedents provided by other mutational 242 signatures with strong transcriptional strand bias suggest that it is likely of exogenous origin^{21,22}. A polymorphism in aldehyde dehydrogenase 2 known to impair metabolism of 243 244 alcohol to aldehydes and common in Japan did not associate with levels of SBS12, and neither 245 did any other common germline variants (Supplementary Note).

246

247 SBS40a, SBS40b, and SBS40c were present in ccRCC from all 11 countries. The country-248 specific average mutation burdens of SBS40a and SBS40b positively associated with countryspecific ASRs of kidney cancer incidence (p-value=0.0022 and p-value=5.1 × 10⁻¹⁸, 249 250 respectively; Extended Data Fig. 8a; Fig. 4a, Supplementary Table 9), with the highest 251 mutation loads in the Czech Republic and Lithuania. Kidney cancer incidence rates also vary 252 between the regions of the Czech Republic and SBS40b mutation burdens differed significantly 253 between these (p-value=0.011; Fig 4b,c, Supplementary Table 10), with the highest 254 attribution in the highest risk region. SBS40b exhibits modest transcriptional strand bias and, 255 assuming that transcription-coupled repair of DNA adducts is responsible, the adducts 256 underlying SBS40b are likely on pyrimidines. Insertion and deletion (indel) signatures ID5 and 257 ID8, which together contributed ~60% of the indel mutation burden on average, were also strongly associated with country-specific kidney cancer ASR (p-value=1.3 × 10⁻¹⁰ and p-258 259 value=7.1 × 10⁻⁵, respectively, **Extended Data Fig. 8b,c**). Signatures ID5 and ID8 correlated 260 with each other (Spearman's r=0.78), as well as with SBS40b (r=0.79 and r=0.74, respectively) 261 indicating that they likely all constitute products of the same underlying mutational process. 262 Thus, the burdens of the full complement of mutation types generated by this mutational process correlate with age-adjusted kidney cancer incidence rates. The overall mutational 263 264 burden did not, however, associate significantly with kidney cancer incidence rates (Extended 265 Data Fig. 9).

266

267 To investigate potential mutagenic agents underlying these geographically variable signatures, 268 an untargeted metabolomics screen of plasma was conducted on 901 individuals in the study, 269 from all countries except Japan (Methods). 2,392 metabolite features were obtained, including 270 944 independent peaks (r<0.85). Three features were associated with SBS4 (Supplementary Table 11), with two identified as hydroxycotinine (p-value=2.9 × 10⁻⁹) and cotinine (p-value=1.9 271 \times 10⁻⁵), two major metabolites of nicotine²⁴. Eight features were associated with SBS40b 272 273 (Supplementary Table 11). One feature was identified as N,N,N-trimethyl-L-alanyl-L-proline betaine (TMAP; p-value= 1.2×10^{-5} , Supplementary Table 12), increased levels of which 274

correlate strongly with reduced kidney function²⁵. Other established measures of kidney function, including cystatin C and creatinine, were correlated with TMAP (p-value = 2.5×10^{-30} and 1.7×10^{-69} , respectively) and also showed evidence of positive association with SBS40b (p-value=0.023 and 0.058, respectively). Thus, exposure to the mutagenic agent responsible for SBS40b is associated with reduced kidney function. No recognized metabolome features were significantly associated with any other signatures.

281

282 A total of 1962 "driver" mutations were found in 136 genes including VHL, PBRM1, SETD2 283 and BAP1, the known frequently mutated cancer genes in ccRCC (Methods) (Fig. 5a, **Supplementary Table 13**)^{9,26}. The frequencies of mutations in these genes were consistent 284 285 across countries (Fig. 5b). The spectrum of all driver mutations in ccRCC with Aristolochic 286 acid exposure (Methods) was enriched in T>A mutations compared to non-exposed cases 287 (25% vs 13%, p-value=0.0062, Fig. 5c,d) with similar enrichment specifically in VHL mutations (30% vs 16%; Fig. 5e,f), and in the whole exomes (27% in exposed compared to 12% in 288 289 unexposed cases). Thus genome-wide Aristolochic acid mutagenesis has contributed in a 290 proportionate fashion to generation of driver mutations in Aristolochic acid-exposed ccRCC. 291 The driver mutation spectrum did not show statistically significant enrichment of T>C mutations 292 in SBS12 exposed cases (20% vs 12%, p = 0.069), but was consistent with the level of 293 enrichment in the exome (21% in exposed compared to 15% in unexposed cases). SBS40b 294 also did not show statistically significant enrichment possibly due to the ubiquitous exposure 295 and its relatively flat and featureless mutation profile.

296

Exogenous mutagenic exposures that ultimately cause cancer may be present during the early stages of evolution of cancer clones. To time mutagenic exposures, the contribution of each mutational signature to mutations in the primary clone (relatively early) and to mutations in subclones (relatively late) were estimated^{27,28} (**Methods**). All signatures of the putative exogenous mutagenic exposures observed in ccRCC were present at relatively early stages of cancer development, consistent with exposures to normal cells. SBS12, SBS22b, and

303 SBS40b showed higher activities in main clones compared to subclones (q-value=0.04, q-304 value=0.02, q-value= 2.3×10^{-5} , respectively) (**Extended Data Fig. 10**) and SBS22a showed 305 no significant difference^{15,16}. By contrast, signatures due to endogenous mutational processes 306 including APOBEC DNA editing (SBS13) and oxidative damage (SBS18), were enriched in 307 subclones (q-value= 1.6×10^{-4} , q-value= 3.2×10^{-7} , respectively).

308

309 Established or suspected risk factors for ccRCC include age, tobacco smoking, obesity, hypertension, diabetes, and environmental exposure to PFAS compounds²⁹. Total SBS, DBS, 310 311 and ID mutation burdens associated with age, as did SBS1, SBS4, SBS5, SBS40a, SBS40b, SBS22a, SBS22b, DBS2, ID1, ID5, and ID8. Total SBS (p-value=3.1 × 10⁻⁵), DBS (p-312 313 value= 3.7×10^{-3}) and ID (p-value= 1.3×10^{-4}) mutation burdens also associated with sex, with 314 males having higher mutation burdens than females, and with SBS40b showing a similar association (p-value= 9.3×10^{-5}). Associations with tobacco smoking were observed for SBS4 315 (p-value= 5.3×10^{-6}) and DBS2 (p-value= 2.4×10^{-7}), both known to be caused by tobacco 316 317 carcinogens^{30,31}. These results suggest that the known increased risk of ccRCC with tobacco 318 smoking is due to direct exposure of the kidney to tobacco related mutagens (Supplementary 319 Note). Associations of particular mutational signatures with other ccRCC risk factors were not 320 observed (Supplementary Tables 14, 15). To complement this analysis of observational data, 321 associations between polygenic risk scores for known ccRCC risk factors and mutational signatures^{32,33} were examined (Methods). Consistent with the observational data, no 322 323 associations were found between genetically inferred risk factors and mutational signatures 324 except for tobacco smoking and DBS2 (p-value=0.01; Supplementary Table 16).

325

326

327 **DISCUSSION**

328 Somatic mutations in the genomes of 962 ccRCC patients from 11 countries indicate the 329 existence of multiple, widespread mutational processes exhibiting substantial geographical 330 variation in their contributions to ccRCC mutation loads. The results contrast with those from 331 552 esophageal squamous carcinomas from eight countries with widely different esophageal 332 carcinoma incidence rates in which geographical differences in mutation burdens or signatures 333 were not observed³⁴. Together the studies implicate both geographically variable mutagenic 334 and non-mutagenic carcinogenic exposures contributing to global cancer incidence. Indeed, 335 the presence of mutational signatures associated with tobacco smoking but absence of 336 signatures associated with other known ccRCC risk factors, such as obesity and hypertension, 337 suggests that the latter may be mediated by non-mutagenic processes and, therefore, that 338 both classes of carcinogen contribute to the development of ccRCC.

339

340 The existence, identity, and carcinogenic effect of some of the agents underlying these 341 mutational processes are known. Aristolochic acids are believed to cause SBS22a/b, and its 342 associated signatures, but this study suggests that the geographical extent and proportion of 343 the population acquiring mutations in South-Eastern Europe is far greater than previously 344 anticipated, possibly affecting 10s of millions of individuals. The sources of the Aristolochic 345 acid exposure, the manner by which it is ingested and whether the exposure continues today 346 are uncertain, and further definition of the source and extent of this exposure is required in 347 order to provide a foundation for public health action.

348

349 The existence of the mutagenic exposures underlying SBS12 and SBS40b were not previously 350 suspected, and their causative agents are unknown. Based on current information, the 351 exposure causing SBS12 is restricted to Japan. However, larger studies are now indicated to 352 explore the geographical extent of exposure in Japan and neighboring countries, and the 353 proportions of their populations that have been exposed. Studies of Japanese migrants to other 354 countries are also likely to be informative regarding the potential source of exposure. In the 355 first instance this will be achievable by further sequencing of kidney and hepatocellular cancer 356 genomes. However, studies of normal tissues, using recently reported sequencing methods allowing detection of somatic mutations in normal cells³⁵, and particularly relatively accessible 357

ones such as cells in urine that can be prospectively collected, may enable large populationbased studies providing better characterization of the exposure and its consequences. As with exposure to Aristolochic acid in South-Eastern Europe, it is possible that 10s of millions of individuals in East Asia are exposed to a potent mutagen, and identification of the source and extent of exposure would seem to be a public health priority.

363

In contrast to Aristolochic acid and the agent causing SBS12, the exposure underlying SBS40b appears to be globally ubiquitous. It predominantly causes mutations in ccRCC, with much lower burdens in other cancer types, and generates mutation loads correlating strongly with age and sex. There are few clues as to its origin or nature.

368

The incidence rates of ccRCC vary ~eightfold across the eleven countries from which ccRCCs were sequenced. A strong positive correlation (p-value= 5.5×10^{-18}) was found between the average mutation loads attributable to SBS40b in each country (and also those of ID5 and ID8 which are correlated with SBS40b) and incidence of kidney cancer within each country. This correlation reflects approximately a tripling of average country-specific SBS40b mutation loads (a difference of ~1000 mutations) in parallel with the eightfold increase of country-specific ASR.

375

376 SBS40b mutation burdens also positively correlated with biomarkers of impaired kidney 377 function, reminiscent of the nephrotoxic effects of Aristolochic acids in Balkan endemic 378 nephropathy. It is possible that the increased SBS40b somatic mutation load itself engenders 379 this reduction in renal function. However, studies of other normal tissues suggest that they are 380 generally tolerant of elevated mutation burdens, except for manifesting a higher incidence of neoplasia^{36,37}. It is also possible that the agent underlying SBS40b is directly nephrotoxic, for 381 382 example by engendering DNA damage and a response to it, and that the mutations it generates are immaterial to kidney function. It is also conceivable, however, that impaired renal 383 384 function, potentially due to many different causes, results in a metabolic state which itself 385 causes the elevated SBS40b mutation load. Whatever the mutational process underlying

386 SBS40b, it is plausible that it contributes to the geographical variation in the age standardized 387 rates of kidney cancer incidence rates. It is of public health interest to determine the cause of 388 SBS40b and, hence, to consider whether the exposure can be mitigated, potentially with 389 concomitant reduction in global ccRCC incidence rates.

390

The absence of any association between several known risk factors for ccRCC and mutation burden, in particular for obesity and hypertension, supports a model of cancer development where mutations are essential but additional factors affect the expansion of a mutated clone and thus the chance of it progressing into cancer³⁸. Further efforts at defining how lifestyle and environmental exposures contribute to cancer development will therefore require a greater understanding of both the causes of the mutations in cell clones in normal tissue, and the further promotion of such mutant clones by non-mutagenic processes.

398

399 Finally, the substantial geographical variability of SBS12 and SBS22a/b, with most countries 400 not showing evidence of exposure, raises the possibility that additional mutational signature 401 studies of ccRCC involving more countries may reveal further mutagenic exposures. 402 Furthermore, the results relating to SBS40b highlight the prospect that a significant proportion 403 of global cancer burden may be caused by relatively ubiquitous exposures that are not readily 404 detectable by classical cancer epidemiology studies. The conduct of large scale whole genome 405 sequencing for other cancer sites across high and low risk populations around the world would 406 seem to be an appropriate strategy for detecting such novel cancer causing agents.

407

408

409 **REFERENCES**

410 1. Brennan, P. & Davey-Smith, G. Identifying Novel Causes of Cancers to Enhance

411 Cancer Prevention: New Strategies Are Needed. JNCI: Journal of the National Cancer

412 *Institute* **114**, 353–360 (2022).

413 2. Hsieh, J. J. et al. Renal cell carcinoma. Nat Rev Dis Primers 3, 17009 (2017).

- 414 3. Koh, G., Degasperi, A., Zou, X., Momen, S. & Nik-Zainal, S. Mutational signatures:
- 415 emerging concepts, caveats and clinical applications. *Nat Rev Cancer* **21**, 619–637
- 416 (2021).
- 417 4. Alexandrov, L. B. *et al.* The repertoire of mutational signatures in human cancer.
- 418 *Nature* **578**, 94–101 (2020).
- 419 5. Scelo, G. *et al.* Variation in genomic landscape of clear cell renal cell carcinoma
- 420 across Europe. *Nat Commun* **5**, 5135 (2014).
- 421 6. Mitchell, T. J. *et al.* Timing the Landmark Events in the Evolution of Clear Cell Renal
- 422 Cell Cancer: TRACERx Renal. *Cell* **173**, 611-623.e17 (2018).
- 423 7. Campbell, P. J. *et al.* Pan-cancer analysis of whole genomes. *Nature* 578, 82–93
 424 (2020).
- 425 8. Degasperi, A. et al. A practical framework and online tool for mutational signature
- 426 analyses show intertissue variation and driver dependencies. *Nat Cancer* 1, 249–263
 427 (2020).
- 428 9. The Cancer Genome Atlas Research Network. Comprehensive molecular
- 429 characterization of clear cell renal cell carcinoma. *Nature* **499**, 43–49 (2013).
- 430 10. Mutographs Cancer Grand Challenge. *https://cancergrandchallenges.org/teams*.
- 431 11. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence
- 432 and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* **71**, 209–
 433 249 (2021).
- 434 12. Nik-Zainal, S. *et al.* Mutational Processes Molding the Genomes of 21 Breast
 435 Cancers. *Cell* **149**, 979–993 (2012).
- 436 13. Alexandrov, L. B. *et al.* Signatures of mutational processes in human cancer. *Nature*437 **500**, 415–421 (2013).
- 438 14. Drost, J. *et al.* Use of CRISPR-modified human stem cell organoids to study the origin
 439 of mutational signatures in cancer. *Science (1979)* **358**, 234–238 (2017).
- 440 15. Hoang, M. L. *et al.* Mutational Signature of Aristolochic Acid Exposure as Revealed by
- 441 Whole-Exome Sequencing. *Sci Transl Med* **5**, (2013).

- 442 16. Poon, S. L. *et al.* Genome-wide mutational signatures of aristolochic acid and its
- 443 application as a screening tool. *Sci Transl Med* **5**, 197ra101 (2013).
- 444 17. Grollman, A. P. Aristolochic acid nephropathy: Harbinger of a global iatrogenic
- 445 disease. *Environ Mol Mutagen* **54**, 1–7 (2013).
- 446 18. Turesky, R. J. et al. Aristolochic acid exposure in Romania and implications for renal
- 447 cell carcinoma. *Br J Cancer* **114**, 76–80 (2016).
- Wang, X.-M. *et al.* Integrative genomic study of Chinese clear cell renal cell carcinoma
 reveals features associated with thrombus. *Nat Commun* **11**, 739 (2020).
- 450 20. Huang, M. N. *et al.* Genome-scale mutational signatures of aflatoxin in cells, mice, and 451 human tumors. *Genome Res* **27**, 1475–1486 (2017).
- 452 21. Haradhvala, N. J. *et al.* Mutational Strand Asymmetries in Cancer Genomes Reveal
- 453 Mechanisms of DNA Damage and Repair. *Cell* **164**, 538–549 (2016).
- 454 22. Nik-Zainal, S. *et al.* The genome as a record of environmental exposure. *Mutagenesis*455 gev073 (2015) doi:10.1093/mutage/gev073.
- 456 23. Sato, Y. *et al.* Integrated molecular analysis of clear-cell renal cell carcinoma. *Nat*457 *Genet* 45, 860–867 (2013).
- 458 24. Dempsey, D. *et al.* Nicotine metabolite ratio as an index of cytochrome P450 2A6
 459 metabolic activity. *Clin Pharmacol Ther* **76**, 64–72 (2004).
- 460 25. Velenosi, T. J. et al. Untargeted metabolomics reveals N, N, N-trimethyl-L-alanyl-L-
- 461 proline betaine (TMAP) as a novel biomarker of kidney function. *Sci Rep* 9, 6831
 462 (2019).
- 463 26. Sato, Y. *et al.* Integrated molecular analysis of clear-cell renal cell carcinoma. *Nat*464 *Genet* 45, 860–867 (2013).
- 465 27. Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994–1007 (2012).
- 466 28. Dentro, S. C., Wedge, D. C. & van Loo, P. Principles of Reconstructing the Subclonal
 467 Architecture of Cancers. *Cold Spring Harb Perspect Med* 7, (2017).
- 468 29. Shearer, J. J. et al. Serum Concentrations of Per- and Polyfluoroalkyl Substances and
- 469 Risk of Renal Cell Carcinoma. J Natl Cancer Inst **113**, 580–587 (2021).

470 30. Nik-Zainal, S. *et al.* The genome as a record of environmental exposure. *Mutagenesis*

471 gev073 (2015) doi:10.1093/mutage/gev073.

- 472 31. Kucab, J. E. *et al.* A Compendium of Mutational Signatures of Environmental Agents.
 473 *Cell* **177**, 821-836.e16 (2019).
- 474 32. Gabriel, A. A. G. et al. Genetic Analysis of Lung Cancer and the Germline Impact on
- 475 Somatic Mutation Burden. *JNCI: Journal of the National Cancer Institute* **114**, 1159–
 476 1166 (2022).
- 477 33. Liu, Y., Gusev, A., Heng, Y. J., Alexandrov, L. B. & Kraft, P. Somatic mutational
 478 profiles and germline polygenic risk scores in human cancer. *Genome Med* 14, 14
- 479 (2022).
- 480 34. Moody, S. *et al.* Mutational signatures in esophageal squamous cell carcinoma from
 481 eight countries with varying incidence. *Nat Genet* 53, 1553–1563 (2021).
- 482 35. Abascal, F. *et al.* Somatic mutation landscapes at single-molecule resolution. *Nature*483 **593**, 405–410 (2021).
- 484 36. Martincorena, I. et al. High burden and pervasive positive selection of somatic

485 mutations in normal human skin. *Science (1979)* **348**, 880–886 (2015).

- 486 37. Martincorena, I. *et al.* Somatic mutant clones colonize the human esophagus with age.
 487 Science (1979) 362, 911–917 (2018).
- 488 38. Fowler, J. C. & Jones, P. H. Somatic Mutation: What Shapes the Mutational
- 489 Landscape of Normal Epithelia? *Cancer Discov* **12**, 1642–1655 (2022).
- 490

491 FIGURE AND TABLE LEGENDS

492 Fig. 1: Eleven participating countries and estimated age-standardized incidence rates

- 493 of clear cell renal cell carcinomas.
- 494 Incidence of clear cell renal cell carcinomas (ccRCC), men and women combined, age-
- 495 standardized incidence rates (ASR) per 100,000, data from GLOBOCAN 2020. Markers
- 496 indicate countries included in this study (number of participating ccRCC patients per
- 497 country).

100	ı.
498	

499	Table 1. Summary of clear cell renal cell carcinomas risk factors included in this
500	study.
501	
502	Fig. 2: Single base substitution signature operative in clear cell renal cell carcinomas.
503	(a) TMB plot showing the frequency and mutations per Mb for each of the decomposed SBS
504	signatures. (b) Average relative attribution for single base substitution (SBS) signatures
505	across countries. Signatures contributing less than 5% on average are grouped in the
506	'Others' category, apart from SBS12 and AA-related signatures SBS22a and SBS22b. '<95%
507	confidence' category accounts for the proportion of mutation burden which could not be
508	assigned to any signature with confidence level of at least 95%. (c) Decomposed signatures,
509	including reference COSMIC signatures as well as de novo signatures not decomposed into
510	COSMIC reference signatures.
511	
512	Fig. 3: Geospatial analysis of Aristolochic acid-related SBS signatures.
513	Distribution of Romanian and Serbian cases with known residential history, along with the
514	summed levels of SBS22a and SBS22b attributions (per-case and regional estimate), with
515	respect to the Balkan endemic nephropathy (BEN) areas. White circles represented cases
516	with no detected activity of SBS22a and SBS22b.
517	
518	Fig. 4: Association of SBS40b signature attribution with incidence of kidney cancer.
519	(a) Number of mutations attributed to signature SBS40b against age-standardized incidence
520	rates (ASR) of kidney cancer in each of the eleven countries represented in the cohort. Error

521 bars represent standard errors of the mean. (b) Number of mutations attributed to signature

522 SBS40b in four regions of Czech Republic against ASR of kidney cancer in each region.

523 Error bars represent standard errors of the mean. In (a) and (b), the p-values are shown for

- 524 the ASR variable in linear regressions across all cases, adjusted for sex and age of
- 525 diagnosis. (c) Levels of attribution of SBS40b signature within Czech Republic, with bar plots

- 526 showing the number of cases for each quartile of SBS40b attribution across Prague,
- 527 Olomouc, Ceske Budejovice, and Brno regions.
- 528

529 Fig. 5: Driver mutation analysis in clear cell renal cell carcinomas.

- 530 (a) Frequency of driver genes in the cohort. Only genes mutated in at least 10 cases are
- shown. (b) Frequency of driver genes across countries. Thailand, Poland and Lithuania are
- not shown due to low sample numbers. (c) SBS-96 mutational spectra of all driver mutations
- 533 in ccRCC for Aristolochic acid (AA)-exposed and unexposed cases. (d) Percentage of T>A
- driver mutations in AA-exposed and unexposed cases. (e) SBS-96 mutational spectra of VHL
- 535 mutations in ccRCC for AA-exposed and unexposed cases. (f) Percentage of T>A VHL
- 536 mutations in AA-exposed and unexposed cases.

537

538 ONLINE METHODS

539 Recruitment of cases and informed consent

540 The International Agency for Research on Cancer (IARC/WHO) coordinated case recruitment 541 through an international network of over 40 collaborators from the 11 participating countries 542 (Table1; Supplementary Table 17). The inclusion criteria for patients were >=18 years of age 543 (ranging from 23 to 87, with a mean of 60 and a standard deviation of 12), confirmed diagnosis 544 of primary ccRCC and no prior cancer treatment. Informed consent was obtained for all 545 participants. Patients were excluded if they had any condition that could interfere with their 546 ability to provide informed consent or if there were no means of obtaining adequate tissues or 547 associated data as per the protocol requirements. Ethical approvals were first obtained from 548 each Local Research Ethics Committee and Federal Ethics Committee when applicable, as 549 well as from the IARC Ethics Committee.

550

551 Bio-samples, data collection, and expert pathology review

552 Dedicated standard operating procedures, following guidelines from the International Cancer 553 Genome Consortium (ICGC), were designed by IARC/WHO to select appropriate case series with complete biological samples and exposure information as described previously¹ 554 555 (Supplementary Table 17). In brief, for all case series included, anthropometric measures 556 were taken, together with relevant information regarding medical and familial history. 557 Comparable smoking and alcohol history was available from all centers. Detailed 558 epidemiological information on residential history was collected in Czech Republic, Romania, 559 and Serbia. Potential limitations of using retrospective clinical data collected using different 560 protocols from different populations were addressed by a central data harmonization to ensure 561 a comparable group of exposure variables (Supplementary Table 17). All patient related data 562 as well as clinical, demographical, lifestyle, pathological and outcome data were pseudonymized locally through the use a dedicated alpha-numerical identifier system before 563 being transferred to IARC/WHO central database. 564

565 Original diagnostic pathology departments provided diagnostic histological details of 566 contributing cases through standard abstract forms. IARC/WHO centralized the entire 567 pathology workflow and coordinated a centralized digital pathology examination of the frozen 568 tumor tissues collected for the study as well as formalin-fixed, paraffin-embedded (FFPE) 569 sections when available, via a web-based report approach and dedicated expert panel 570 following standardized procedures as described previously¹. A minimum of 50% viable tumor 571 cells was required for eligibility to whole genome sequencing.

In summary, frozen tumor tissues were first examined to confirm the morphological type and the percentage of viable tumor cells. A random selection of tumor tissues was independently evaluated by a second pathologist. Enrichment of tumor component was performed by dissection of non-tumoral part, if necessary. 90 cases overlapped with a previously published cohort recruited under the Cancer Genomics of the Kidney (CAGEKID) project², which were also part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) project³.

578

579 **DNA extraction**

Extraction of DNA from fresh frozen tumor and matched blood samples was centrally conducted at IARC/WHO except for Japan, which performed DNA extractions at the local center following a similarly standardized DNA extraction procedure. Of the cases which proceeded to the final analysis (n=962), germline DNA was extracted from either buffy-coat, whole blood, or from adjacent normal tissue (*viz.*, samples from Japan) using previously described protocols and methods¹.

586

587 Whole genome sequencing

In total, 1583 renal cell carcinoma cases were evaluated, with 1267 confirmed as ccRCC cases. 116 (9%) were excluded due to insufficient viable tumor cells (pathology level), or inadequate DNA (tumor or germline). DNA from 1151 cases was received at the Wellcome Sanger Institute for whole genome sequencing. Fluidigm SNP genotyping with a custom panel was performed to ensure that each pair of tumor and matched normal samples originated from

593 the same individual. Whole genome sequencing (150bp paired end) was performed on the 594 Illumina NovaSeg 6000 platform with target coverage of 40X for tumors and 20X for matched 595 normal tissues. All sequencing reads were aligned to the GRCh38 human reference genome 596 using Burrows-Wheeler-MEM (v0.7.16a and v0.7.17). Post-sequencing QC metrics were 597 applied for total coverage, evenness of coverage and contamination. Cases were excluded if 598 coverage was below 30X for tumor or 15X for normal tissue. For evenness of coverage, the 599 median over mean coverage (MoM) score was calculated. Tumors with MoM scores outside 600 the range of values determined by previous studies to be appropriate for whole genome sequencing (0.92 – 1.09) were excluded. Conpair⁴ (https://github.com/nygenome/Conpair) 601 was used to detect contamination, cases were excluded if the result was greater than 3%⁵. A 602 603 total of 962 cases passed all criteria and were included in subsequent analysis.

604

605 Somatic variant calling

Variant calling was performed using the standard Sanger bioinformatics analysis pipeline 606 607 (https://github.com/cancerit). Copy number profiles were determined first using the algorithms ASCAT⁶ and BATTENBERG⁷, where tumor purity allowed. SNV were called with 608 cqpCaVEMan⁸, indels were called with cqpPINDEL⁹, and structural rearrangements were 609 610 called using BRASS. CaVEMan and BRASS were run using the copy number profile and purity 611 values determined from ASCAT where possible (complete pipeline, n=857). Where tumor 612 purity was insufficient to determine an accurate copy number profile (partial pipeline, n=105). 613 CaVEMan and BRASS were run using copy number defaults and an estimate of purity 614 obtained from ASCAT/BATTENBERG. For SNV additional filters (ASRD >= 140 and CLPM 615 ==0) were applied to remove potential false positive calls. A second variant caller, Strelka2, 616 was run for SNVs and indels as consensus variant calling was previously shown to eliminate 617 algorithm specific artefacts and to generate highly reproducible mutational spectra compared to using a single variant calling algorithm^{1,10}. Only variants called by both the Sanger variant 618 619 calling pipeline and Strelka2 were included in subsequent analysis.

620

621 Validation of Japanese sequencing

The matched normal tissue sequenced was blood for all countries with the exception of Japan, where adjacent normal kidney was used. As Japan displayed an enrichment of SBS12, matched blood was obtained from 28 of the 36 patients to confirm that the source of the matched normal tissue was not influencing the result. In all cases, the mutational spectra of Japanese ccRCC generated using either blood or adjacent normal kidney matched each other with a cosine similarity of >0.99.

628

629 Generation of mutational matrices

630 Mutational matrices for single base substitutions (SBS), doublet base substitutions (DBS) and 631 small insertions and deletions (ID) were generated using SigProfilerMatrixGenerator 632 (<u>https://github.com/AlexandrovLab/SigProfilerMatrixGenerator</u>) with default options 633 (v1.2.12)¹¹.

634

635 Mutational signature analysis

636 **Mutational** signatures were extracted using two algorithms, SigProfilerExtractor 637 (https://github.com/AlexandrovLab/SigProfilerExtractor), based on nonnegative matrix factorization, and mSigHdp¹² (<u>https://github.com/steverozen/mSigHdp</u>), based on the 638 639 Bayesian hierarchical Dirichlet process. For SigProfilerExtractor, de novo mutational 640 signatures were extracted from each mutational matrix using SigProfilerExtractor with nndsvd_min initialization (NMF_init="nndsvd_min") and default parameters (v1.1.9)¹³. Briefly, 641 SigProfilerExtractor deciphers mutational signatures by first performing Poisson resampling of 642 643 the original matrix with additional renormalization (based on a generalized mixture model approach) of hypermutators to reduce their effect on the overall factorization¹³. Nonnegative 644 645 matrix factorization (NMF) was performed using initialization with nonnegative singular value decomposition and by applying the multiplicative update algorithm using the Kullback-Leibler 646 divergence as an objective function¹³. NMF was applied with factorizations between k=1 and 647 k=20 signatures; each factorization was repeated 500 times¹³. De novo single base 648

649 substitution mutational signatures were extracted with SigProfilerExtractor for both SBS-288 650 and SBS-1536 contexts¹¹. The results were largely concordant with the SBS-1536 de novo 651 signatures allowing additional separation of mutational processes, therefore the SBS-1536 de 652 novo signatures were taken forward for further analysis (Supplementary Table 3). Mutational signatures for DBS and ID were extracted in DBS-78 and ID-83 contexts respectively 653 654 (Supplementary Tables 4, 5). Where possible, SigProfilerExtractor matched each de novo 655 extracted mutational signature to a set of previously identified COSMIC signatures¹⁴, for SBS-656 1536 signatures this requires collapsing the 1536 classification into the standard 96 657 substitution type classification with six mutation classes having single 3' and 5' sequence 658 contexts (Supplementary Table 8). This step makes it possible to distinguish between de 659 novo signatures which can be explained by a combination of the known catalog of mutational 660 process (which have not been completely separated during the extraction), and those which 661 have not been previously identified. mSigHdp extraction of SBS-96 and ID-83 signatures was 662 performed using the suggested parameters and using the country of origin to construct the 663 hierarchy. SigProfilerExtractor's decomposition module was subsequently used to match mSigHdp *de novo* signatures to previously identified COSMIC signatures¹⁴. Further details on 664 665 the comparison of results between SigProfilerExtractor and mSigHdp and decomposition of de 666 novo signatures into COSMIC reference signatures can be found in the **Supplementary Note**.

667

668 Attribution of activities of mutational signatures

669 The de novo (SigProfiler) and COSMIC signature (SigProfiler and mSigHdp) activities were 670 attributed for each sample usina the MSA signature attribution tool (v2.0. 671 https://gitlab.com/s.senkin/MSA)¹⁵. For COSMIC attributions, only COSMIC reference 672 signatures, which were identified in the decomposition of *de novo* signatures, were included in 673 the panel for attribution, in addition to *de novo* signatures which could not be decomposed into 674 COSMIC reference. At its core, the tool utilizes the nonnegative least squares (NNLS) 675 approach minimizing the L2 distance between the input sample and the one reconstructed 676 using available signatures. To limit false positive attributions, an automated optimization procedure was applied by repeated removal of all signatures that do not increase the L2 similarity of a sample by >0.008 for SBS, >0.014 for DBS, and >0.03 for ID mutation types, as suggested by simulations. These optimal penalties were derived using an optional parameter (params.no_Cl_for_penalties = false) utilizing a conservative approach in calculation of penalties. Finally, a parametric bootstrap approach was applied to extract 95% confidence intervals for each attributed mutational signature activity.

683

684 **Driver mutations**

A dNdS approach was used to identify genes under positive selection in ccRCC¹⁶. The analysis 685 686 was performed both for the whole genome (q-value<0.01), and with restricted hypothesis testing (RHT) for a panel of 369 known cancer genes¹⁶. Variants in any gene identified as 687 under positive selection in global dNdS or in the 369-cancer gene panel were assessed as 688 potential drivers¹⁶. Candidate driver mutations were annotated with the mode of action using 689 690 the Cancer Gene Census (https://cancer.sanger.ac.uk/census) and the Cancer Genome 691 Interpreter tool (https://www.cancergenomeinterpreter.org). Missense mutations were 692 assessed using the MutationMapper tool (http://www.cbioportal.org/mutation mapper). 693 Variants were considered likely drivers if they met any of the following criteria: (i) Truncating 694 mutations in genes annotated as tumor suppressors; (ii) mutations annotated as likely or 695 known oncogenic in MutationMapper; (iii) truncating variants in genes with selection (g-696 value<0.05) for truncating mutations assumed to be tumor suppressors and thus likely drivers: 697 (iv) missense variants in all genes under positive selection and with dN/dS ratios for missense 698 mutations above 5 (assuming 4 of every 5 missense mutations are drivers) labelled as likely 699 drivers; or (v) in-frame indels in genes under significant positive selection for in-frame indels.

700

701 Evolutionary analysis

Subclonal architecture reconstruction was performed using the DPClust R package v2.2.8^{7,17},
after obtaining cancer cell fraction (CCF) estimates by dpclust3p v1.0.8
(https://github.com/Wedge-lab/dpclust3p) based on the variant allele frequency provided by

705 the somatic variant callers and the copy number profiles determined by the BATTENBERG algorithm. Only tumors with at least 40% purity according to BATTENBERG were considered 706 for further evolutionary analysis. For each tumor with at least one subclone, the respective 707 708 somatic mutations were split into clonal and subclonal mutations using the most probable 709 cluster assignment for each mutation as per the DPClust output. Mutations not assigned to a 710 cluster by DPClust were removed from further analysis. Clusters centered at a CCF>1.5 and 711 ones where chromosome X contributed the highest number of mutations were deemed 712 artifactual, and the respective mutations were removed. Samples with a total number of clonal 713 or subclonal mutations below 256 were also removed. Additionally, samples with poor 714 separation between the clonal and subclonal distributions (e.g., subclone centered at a 715 CCF>0.80) were removed. Finally, only samples that had both a clone and at least one 716 subclone post-filtering were retained for further analysis. This yielded a total of 223 samples, 717 each with clonal and subclonal mutations. SigProfilerAssignment (v0.0.13) 718 (https://github.com/AlexandrovLab/SigProfilerAssignment) was used to identify the activity of 719 each mutational signature in each clone/subclone, and these activities were then normalized 720 by the total number of mutations belonging to the clone/subclone (*i.e.*, clonal mutations were not included in the subclone). A two-sided Wilcoxon Signed-Rank Test¹⁸ was used to assess 721 722 the differences in the relative activity of each mutational signature between the clones and 723 their respective subclones. P-values were corrected using the Benjamini-Hochberg procedure¹⁹ and reported as q-values in the manuscript. 724

725

726 Regressions

Signature attributions were dichotomized into presence and absence using confidence intervals, with presence defined as both lower and upper limits being positive, and absence as the lower limit being zero. If a signature was present in at least 75% of cases (SBS1, SBS40a, SBS40b, ID1, and ID5), it was dichotomized into above and below the median of attributed mutation counts. The binary attributions served as dependent variables in logistic regressions, and relevant risk factors were used as factorized independent variables. To adjust for

733 confounding factors, sex, age of diagnosis, country, and tobacco status were added as covariates in regressions. The Bonferroni method was used to test for significant p-values (*i.e.*, 734 735 a total of 224 comparisons for regressions with signatures, and a total of 24 comparisons for 736 regressions with mutation burden). P-values reported are raw (not corrected). Regressions 737 with incidence of renal cancer were performed as linear regressions with mutation burdens or 738 signature attributions (those present in at least 75% of cases) with confidence intervals not 739 consistent with zero as a dependent variable, and age-standardized rates (ASR) of renal cancer obtained from Global Cancer Observatory (GLOBOCAN)²⁰, sex and age of diagnosis 740 741 as independent variables. ASR of renal cancer for regions of Czech Republic were obtained from SVOD web portal²¹. Signatures present in less than 75% of cases were dichotomized into 742 743 presence and absence as previously mentioned and analyzed using the logistic regressions. 744 All regressions were performed on a sample basis.

745

746 Polygenic risk score (PRS) analysis of lifestyle risk factors

747 In this analysis, we used the genome-wide association studies (GWAS) summary statistics 748 estimated in European populations for well-established risk factors for ccRCC. For tobacco 749 smoking status, we used results from the GSCAN consortium meta-analysis of smoking initiation (ever vs never status)²². For body mass index (BMI), the results of UK biobank (UKBB) 750 751 and GIANT consortium meta-analysis of continuous BMI were used²³. GWAS summary 752 statistics related to hypertension, namely systolic blood pressure and diastolic blood pressure, as well as the ones related to diabetes²⁴, such as fasting glucose and fasting insulin were also 753 obtained using UKBB studies²⁵. 754

755

Since all the GWAS summary statistics used in the current work were based on European populations, we used ADMIXTURE tool (v1.3.0)²⁶ and principal component analysis (PCA) to infer the unsupervised cluster of individuals with European genetic background within ccRCC cases. Hapmap SNPs (n=1,176,821 variants) were extracted from the ccRCC whole-genome sequence genotype data. After basic quality control using PLINK (v1.9b, www.cog-

761 genomics.org/plink/1.9/), 333 variants were removed due to missing genotype rate > 5%, 1,236 variants failed Hardy-Weinberg equilibrium test (p-values<10⁻⁸), and 18,702 variants had 762 763 MAF<1% in our cohort. Additionally, 3 ambiguous variants and 21,358 variants within regions 764 of long-range, high linkage disequilibrium (LD) in the human genome (hg38) were excluded. After pruning for linkage disequilibrium, 143,727 variants remained in ccRCC genotype data. 765 The 1000 genome reference population genotype data (phase 3) for Europeans (N=489), 766 767 Africans (YRI, N=108) and East Asians (N=103 from China and 104 from Japan) 768 (https://www.internationalgenome.org/data/) were filtered and merged with ccRCC genotype 769 data based on the pruned set of variants present in both datasets. ADMIXTURE was run on 770 the merged genotype data with k=3, which would correspond to the three ancestral continental 771 population groups that likely reflect the participants of our study. The ccRCC cases with 772 European genetic fraction greater than 80% by the ADMIXTURE analysis were selected for 773 the polygenic risk scores (PRS) analyses. To complement the ADMIXTURE analysis, PCA 774 was run on the same samples.

775

776 The initial genotype data based on whole-genome sequence from 849 ccRCC cases with 777 European genetic background consisted of biallelic SNPs with MAF >0.01% (to exclude ultra-778 rare variants; N \sim 30 million variants). After basic quality control, variants with missing 779 genotype rate of greater than 5% (N=7,519,196 variants) with strong deviation from Hardy-780 Weinberg equilibrium (p-values<10⁻⁸, N=220,862) were excluded. For each GWAS trait, we 781 restricted our analyses to the biallelic SNPs with minor allele frequency (MAF) greater than 1% 782 in the 1000 genomes reference for European populations. For the selection of the independent 783 genome-wide significant hits (p-values<5 × 10⁻⁸) of each GWAS summary statistic used to generate the PRS, SNPs were clumped (r²=0.1 within a LD window of 10 MB) using PLINK 784 785 (v1.9b, www.cog-genomics.org/plink/1.9/) based on the 1000 genomes European reference 786 population genotype data (N=489; ~ 10 million variants). Where a selected GWAS hit was not 787 found in ccRCC genotype data, we extracted proxies (r^2 >0.8 in 1000 genomes) also present 788 in ccRCC dataset where possible (Supplementary Table 18). The variance of each genetic

trait explained by the genetic variants were calculated as previously suggested²⁷. PRS was
subsequently calculated as the sum of the individual's beta-weighted genotypes using PRSice2 software²⁸. Associations were estimated per standard deviation increase in the PRS, which
was normalized to have a mean of zero across ccRCC cases of European genetic ancestry.

794 Untargeted metabolomics association with signatures

795 Of the 962 subjects from the main analysis, 901 subjects were included in this sub-study – all 796 Japanese samples (n=36) as well as few cases from Czech Republic (n=13), Romania (n=5) 797 and Russia (n=3) were not included due to lack of available plasma samples. Samples were 798 randomized and analyzed as two independent analytical batches. Analysis was performed with 799 a UHPLC-QTOF-MS system that consisted of a 1,290 Binary LC and a 6,550 QTOF mass 800 spectrometer equipped with Jet Stream electrospray ionization source (Agilent Technologies), using previously described methods²⁹. Pre-processing was performed using Profinder 801 10.0.2.162 and Mass Profiler Professional B.14.9.1 software (Agilent Technologies). A "Batch 802 803 recursive feature extraction (small molecules)" process was employed for samples and blanks 804 to find [M+H]⁺ ions. The two batches were processes separately and the resulting features 805 were aligned in Mass Profiler Professional. Chromatographic peak areas were used as a 806 measurement of intensity. No normalization or transformation of raw data was performed prior 807 to the downstream data analysis.

808

809 A total of 2,392 features were detectable in at least one of the 901 samples. Features present 810 in only one of the two batches were filtered out. Recursive filtering elimination was applied to 811 decrease redundancy from highly correlated variables (r≥0.85, Pearson's r calculated before 812 any transformation/imputation) by selecting the features with least missing data within clusters 813 of features. A total of 944 features were included in the statistical analysis. Features were pre-814 processed: missing values were replaced with 1/5 of the minimal value of the feature before 815 applying mean centering and Pareto scaling. Each feature was regressed against both *de novo* 816 and COSMIC signatures, adjusting for sex and age of diagnosis, as well as body mass index

817 (BMI) and technical factors (batch, acquisition order) that could impact chromatographic peak 818 area. Models for SBS22a and SBS22b were restricted to Romanian and Serbian samples to 819 find potential pathways of Aristolochic acid exposure in the Balkan region. Logistic models 820 were used for zero-inflated signatures (≥30% zeros) while quasi-Poisson regressions were 821 used for the least zero-inflated signatures (SBS1, SBS40a, and SBS40b). To derive specific 822 false detection rates, random variables were created from permutations of the initial features 823 and regressed against signatures in the same fashion as true features. Maximum p-value 824 thresholds from regressions with random features were compared to adjusted p-value 825 thresholds according to Bonferroni's procedure. The more conservative approach was used in 826 selecting features of interest. Random forest models were also used as cross-checking 827 multivariate models to assess the relative importance of each feature in explaining the 828 signature attribution. As with univariate models, regression models were used for the least 829 zero-inflated signatures (<30% of zeros) while classification models were used for all other 830 signatures, with restriction to Romanian and Serbian samples for SBS22a and SBS22b. 831 Importance was estimated from the total decrease in node impurities from splitting on the 832 variable, averaged over all trees. Node impurity was measured by the Gini index for 833 classification, and by residual sum of squares for regression. The significance of importance 834 metrics for Random Forest models were estimated by permuting the response variable 835 (https://github.com/EricArcher/rfPermute).

836

837 Features considered for identification, along with their highly correlated counterparts, were 838 searched in Human Metabolome Database (HMDB), LipidMaps, Metlin, and Kegg. Compound 839 identity was confirmed by comparison of retention times and MS/MS fragmentation against 840 chemical standards when available, or otherwise against reference MS/MS spectra. Since the 841 feature 240.1468@0.8929933 was strongly correlated with several features identified as 842 TMAP (Supplementary Table 11), the integration of these features was inspected and 843 corrected manually, and regressed against SBS40b using the same model applied to features 844 selected for analysis. Creatinine was identified among the features by matching its retention

time and MS/MS spectra against a reference standard and also regressed against SBS40b in
the same fashion as other metabolites. Estimation of correlation between metabolic features
was done using linear regression adjusting for batch and acquisition order.

848

849 Targeted metabolomics analyses

Circulating levels of PFAS (Per- and Polyfluorinated Substances) and cystatin C compounds
 were investigated using targeted mass spectrometry-based methods as described
 previously^{30,31}.

853

854 Out of the 962 subjects from the main analysis, plasma samples from 909 subjects (from all 855 countries except Japan) were randomized and sent frozen in dry ice to each respective 856 laboratory for analyses. Measurement of cystatin C from 906 subjects included its native form 857 and isoforms (3Pro-OH cystatin C, cystatin C-desS, 3Pro-OH cystatin C-desS and cystatin C-858 desSSP) that were modeled individually and for the total concentration of cystatin C isoforms. 859 Measurements of PFAS compounds included PFOA (Perfluorooctanoic Acid; total, branch, 860 linear), PFOS (Perfluorooctanoic Acid; total, branch, linear), PFHxS (Perfluorohexane 861 sulfonate), PFNA (Perfluorononanoic acid), PFDA (Perfluorodecanoic acid), MePFOSAA (n-862 methylperfluoro-1 octanesulfonamido acetic acid), EtPFOSAA (2-(N-Ethyl-perfluorooctane. 863 sulfonamido) acetic acid).

864

Multivariable quasi-Poisson (for the least sparse signatures SBS1, SBS40a and SBS40b) and logistic regression were used to estimate the association between plasma concentrations of the aforementioned substances and mutational signatures. All compounds were modeled continuously (log2-transformed) and categorically, with adjustments made by sex, age, date of recruitment, country, BMI, tobacco and alcohol status in the case of PFAS molecules and by sex, age and BMI, in the case of cystatin C.

871

872

873 Geospatial analyses

874 Geospatial analyses were performed to estimate the regional effect for signature attribution, 875 particularly for signatures thought to be from exogenous exposure (SBS40b - unknown - and 876 SBS22a/SB22b - Aristolochic acid). Residential history information was available for a large 877 proportion of cases from the countries of interest: Czech Republic for SBS40b and 878 Romania/Serbia for SBS22a/SBS22b. The 259 cases from Czech Republic within this study 879 were recruited from 4 separate regions including Prague, České Budějovice (in Southern 880 Bohemia), as well as Brno and Olomouc in the east of the country. Each individual residence 881 was geocoded to its administrative region. All locations outside the country of recruitment were 882 labeled as "Abroad". A multi-membership mixed model was used to account for the full list of 883 regions in which each subject resided, as well as the proportion of life spent in that region 884 before diagnosis. As dependent variable, signatures were inverse-normal transformed. Models 885 were adjusted for sex and age of diagnosis (fixed effects). The regional effect was treated as 886 random effect.

887

888 Data availability

Whole genome sequencing data and patient metadata are deposited in the European Genome-phenome Archive (EGA) associated with study EGAS00001003542. Aligned BAM files for all ccRCC cases included in the final analysis were deposited in dataset EGAD00001012102, variant calling files in dataset EGAD00001012222 and patient metadata in dataset EGAD00001012223. The metabolomics data are available upon request. All other data are provided in the accompanying **Supplementary Tables**.

895

896 **Code availability**

All algorithms used for data analysis are publicly available with repositories noted within the respective method sections and in the accompanying reporting summary. Code used for regression analysis and figures is available at:

900 https://gitlab.com/Mutographs/Mutographs RCC.

901										
902										
903	Methods references									
904	1.	Moody, S. et al. Mutational signatures in esophageal squamous cell carcinoma from								
905		eight countries with varying incidence. Nat Genet 53, 1553–1563 (2021).								
906	2.	Scelo, G. et al. Variation in genomic landscape of clear cell renal cell carcinoma								
907		across Europe. <i>Nat Commun</i> 5 , 5135 (2014).								
908	3.	Campbell, P. J. et al. Pan-cancer analysis of whole genomes. Nature 578, 82–93								
909		(2020).								
910	4.	Whalley, J. P. et al. Framework for quality assessment of whole genome cancer								
911		sequences. Nat Commun 11, 5040 (2020).								
912	5.	Bergmann, E. A., Chen, BJ., Arora, K., Vacic, V. & Zody, M. C. Conpair:								
913		concordance and contamination estimator for matched tumor-normal pairs.								
914		<i>Bioinformatics</i> 32 , 3196–3198 (2016).								
915	6.	Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proceedings of the								
916		National Academy of Sciences 107, 16910–16915 (2010).								
917	7.	Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994–1007 (2012).								
918	8.	Jones, D. et al. cgpCaVEManWrapper: Simple Execution of CaVEMan in Order to								
919		Detect Somatic Single Nucleotide Variants in NGS Data. Curr Protoc Bioinformatics								
920		56 , (2016).								
921	9.	Raine, K. M. et al. cgpPindel: Identifying Somatically Acquired Insertion and Deletion								
922		Events from Paired End Sequencing. Curr Protoc Bioinformatics 52, (2015).								
923	10.	Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat								
924		Methods 15 , 591–594 (2018).								
925	11.	Bergstrom, E. N. et al. SigProfilerMatrixGenerator: a tool for visualizing and exploring								
926		patterns of small mutational events. BMC Genomics 20, 685 (2019).								

- 927 12. Liu, M., Wu, Y., Jiang, N., Boot, A. & Rozen, S. G. mSigHdp: hierarchical Dirichlet
- 928 process mixture modeling for mutational signature discovery. *bioRxiv*
- 929 2022.01.31.478587 (2022) doi:10.1101/2022.01.31.478587.
- 930 13. Islam, S. M. A. *et al.* Uncovering novel mutational signatures by de novo extraction
- 931 with SigProfilerExtractor. *Cell genomics* **2**, None (2022).
- 932 14. Alexandrov, L. B. *et al.* The repertoire of mutational signatures in human cancer.
- 933 *Nature* **578**, 94–101 (2020).
- 934 15. Senkin, S. MSA: reproducible mutational signature attribution with confidence based
 935 on simulations. *BMC Bioinformatics* 22, 540 (2021).
- 936 16. Martincorena, I. *et al.* Universal Patterns of Selection in Cancer and Somatic Tissues.
 937 *Cell* **171**, 1029-1041.e21 (2017).
- 938 17. Dentro, S. C., Wedge, D. C. & van Loo, P. Principles of Reconstructing the Subclonal
 939 Architecture of Cancers. *Cold Spring Harb Perspect Med* 7, (2017).
- 940 18. Wilcoxon, F. Individual Comparisons by Ranking Methods. *Biometrics Bulletin* 1, 80
 941 (1945).
- 942 19. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and
- 943 Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series*
- 944 *B (Methodological)* **57**, 289–300 (1995).
- 945 20. Sung, H. *et al.* Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence
 946 and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* **71**, 209–
 947 249 (2021).
- 948 21. Dušek, L. et al. Epidemiology of Malignant Tumours in the Czech Republic
- 949 [online]. Masaryk University, Czech Republic, [2005]. *http://www.svod.cz/. Version 7.0*950 [2007], ISSN 1802 8861.
- 22. Liu, M. *et al.* Association studies of up to 1.2 million individuals yield new insights into
 the genetic etiology of tobacco and alcohol use. *Nat Genet* **51**, 237–244 (2019).

- 953 23. Yengo, L. et al. Meta-analysis of genome-wide association studies for height and body
- 954 mass index in ~700000 individuals of European ancestry. *Hum Mol Genet* 27, 3641–
 955 3649 (2018).
- 24. Lagou, V. *et al.* Sex-dimorphic genetic effects and novel loci for fasting glucose and
 insulin variability. *Nat Commun* **12**, 24 (2021).
- 958 25. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
- 959 *Nature* **562**, 203–209 (2018).
- 960 26. Alexander, D. H., Novembre, J. & Lange, K. Fast model-based estimation of ancestry
 961 in unrelated individuals. *Genome Res* 19, 1655–1664 (2009).
- 962 27. Shim, H. et al. A Multivariate Genome-Wide Association Analysis of 10 LDL
- 963 Subfractions, and Their Response to Statin Treatment, in 1868 Caucasians. *PLoS*
- 964 *One* **10**, e0120758 (2015).
- 965 28. Choi, S. W. & O'Reilly, P. F. PRSice-2: Polygenic Risk Score software for biobank966 scale data. *Gigascience* 8, (2019).
- 967 29. Loftfield, E. et al. Novel Biomarkers of Habitual Alcohol Intake and Associations With
- 968 Risk of Pancreatic and Liver Cancers and Liver Disease Mortality. *JNCI: Journal of the*969 *National Cancer Institute* **113**, 1542–1550 (2021).
- 970 30. Shearer, J. J. *et al.* Serum Concentrations of Per- and Polyfluoroalkyl Substances and
 971 Risk of Renal Cell Carcinoma. *J Natl Cancer Inst* **113**, 580–587 (2021).
- 972 31. Gao, J., Meyer, K., Borucki, K. & Ueland, P. M. Multiplex Immuno-MALDI-TOF MS for
- 973 Targeted Quantification of Protein Biomarkers and Their Proteoforms Related to
- 974 Inflammation and Renal Dysfunction. *Anal Chem* **90**, 3366–3373 (2018).
- 975

976 Acknowledgements

- 977 The authors would like to thank Laura O'Neill, Kirsty Roberts, Katie Smith, Maisie Farenden,
- 978 Siobhan Austin-Guest and the staff of DNA Pipelines at the Wellcome Sanger Institute for their
- 979 contribution. We are grateful for the support provided by Maja Milojevic, Christophe Lallemand,
- 980 Helene Renard, Aude Bardot, Andreea Spanu and Nivonirina Robinot as well as IARC General

981 Services, including the Laboratory Services and Biobank team led by Zisis Kozlakidis, the 982 Section of Support to Research overseen by Tamas Landesz and the Evidence Synthesis and 983 Classification Section led by Ian Cree, under IARC regular budget funding. The authors would 984 like to thank Gislaine Bergo, Riley Cox and Juliana Oliveira for help with data/sample 985 preparation and processing. The authors would also like to acknowledge the contributions of 986 the Leeds Biobanking and Sample Processing Lab, the Leeds Multidisciplinary RTB and the 987 Leeds NIHR BioRTB for provision of samples. The authors would like to thank Peter Campbell, 988 Inigo Martincorena, Tim Butler, Daniela Mariosa, Laura Torrens Fontanals, Wellington Oliveira 989 Dos Santos, Hana Zahed, Marc Gunter, Maggie Blanks and Mimi McCord for useful 990 discussions. The authors would also like to thank all the patients and their families involved in 991 this study.

992

993 Funding

994 This work was delivered as part of the Mutographs team supported by the Cancer Grand 995 Challenges partnership funded by Cancer Research UK (C98/A24032). This work was 996 supported by the Wellcome Trust grants 206194 and 220540/Z/20/A. The work was also partly 997 funded by Barretos Cancer Hospital, the Public Ministry of Labor of Campinas (Research, 998 Prevention, and Education of Occupational Cancer, 2015 to R.M.R.), and by Hospital de 999 Clínicas de Porto Alegre (180330 to P.A.-P., M.B., B.S.N.). The work was also partly supported 1000 by the Practical Research Project for Innovative Cancer Control from the Japan Agency for 1001 Medical Research and Development (AMED) (JP20ck0106547h0001 to T.S.), and by the 1002 National Cancer Center Japan Research and Development Fund (2020-A-7 to A.F.). The work was also partly funded by the 1st and 2nd Faculties of Medicine, Charles University, Prague 1003 1004 (CAGEKID to I.H.; Occupation, Environment and Kidney Cancer in Central and Eastern 1005 Europe to A.H.). The work was also partly supported by the Ministry of Health of the Czech Republic (MH CZ - DRO (MMCI, 00209805) to L.F. and M.N.). Measurement of PFAS 1006 1007 compounds was funded by Division of Cancer Epidemiology and Genetics of the National

1008 Cancer Institute (USA). Measurement of cystatin C was funded by Cancer Research UK1009 (C18281/A29019).

1010

1011 **Contributions**

1012 The study was conceived, designed and supervised by M.R.S., P.B. and L.B.A. Analysis of 1013 data was performed by S.Senkin, S.Moody, M.D.-G., T.C., A.F.-I., J.W., S.F., M.K., R.V., 1014 A.P.L., E.N.B., A.K., B.O., S.C., E.T., J.A., K.S.-B., R.C.C.P., V.G., D.J., J.W.T. and J.M. 1015 Pathology review was carried out by B.A.-A., S.F. and M.A. Sample manipulation was carried out by C.L., C.C. and P.C. Patient and sample recruitment was led or facilitated by 1016 1017 S.Sangkhathat, W.A., B.S., S.J., R.S., D.M., V.Jinga, S.R., S.Milosavljevic, M.M., S.Savic, 1018 J.M.S.B, M.A., L.P., P.A.-P., M.B., B.S.N., S.M.B., M.P.C., S.C.Z., R.M.R., E.F., N.S.M., 1019 R.S.F., R.B., N.V., D.Z., A.M., O.S., V.M., L.F., M.N., I.H., A.H., V.Janout, S.C. and C.L., M.P. 1020 P.K.-R., S.C., M.P., P.M.U. and M.J. contributed to data generation. Patient and sample recruitment for Japanese cases was led by T.S. and A.F. Scientific project management was 1021 1022 carried out by L.H., E.C., G.S., A.C.D.C., A.F.-I. and S.P. S.Moody and S.Senkin jointly 1023 contributed and were responsible for overall scientific coordination. The manuscript was 1024 written by S.Senkin, S.Moody, M.R.S. and P.B. with contributions from all other authors.

1025

1026 Competing interests

1027 LBA is a compensated consultant and has equity interest in io9, LLC and Genome Insight. His spouse is an employee of Biotheranostics, Inc. LBA is also an inventor of a US Patent 1028 1029 10,776,718 for source identification by non-negative matrix factorization. ENB and LBA declare 1030 U.S. provisional applications with serial numbers: 63/289,601; 63/269,033; and 63/483,237. 1031 LBA also declares U.S. provisional applications with serial numbers: 63/366,392; 63/367,846; 1032 63/412.835: and 63/492.348. VM received honoraria from Ipsen. Baver. AstraZeneca. Janssen, Astellas Pharm and MSD, and provided expert testimony to BMS, Bayer, MSD and 1033 1034 Janssen. No other authors declare any competing interests.

1035

1036 Disclaimer

1037 Where authors are identified as personnel of the International Agency for Research on Cancer

- 1038 / World Health Organization, the authors alone are responsible for the views expressed in this
- 1039 article and they do not necessarily represent the decisions, policy or views of the International
- 1040 Agency for Research on Cancer / World Health Organization.
- 1041

1042 Corresponding author

- 1043 Correspondence to Paul Brennan.
- 1044

1045 EXTENDED DATA FIGURE AND TABLE LEGENDS

1046 Extended Data Fig. 1: Mutation burdens in clear cell renal cell carcinomas across

- 1047 countries.
- 1048 Mutation burdens for single base substitutions (SBS) (a), doublet base substitutions (DBS)
- 1049 (b) and small insertions and deletions (ID) (c) show significant differences between countries
- 1050 using the Kruskal-Wallis (two-sided) test (n=961 biologically independent samples). Four
- 1051 SBS hypermutators and four ID hypermutators above mutation burden of 30000 and 3000,
- respectively, were removed for clarity. Box and whiskers plots are in the style of Tukey. The
- 1053 line within the box is plotted at the median while the upper and lower ends are indicated 25th
- 1054 and 75th percentiles. Whiskers show 1.5*IQR (interquartile range) and values outside it are
- 1055 shown as individual data points.
- 1056

1057 Extended Data Fig. 2: Principal component analysis of relative mutation counts.

- 1058 PCA performed on relative mutation counts of all ccRCC tumors incorporating the six
- 1059 mutation classes (C>A, C>G, C>T, T>A, T>C, T>G). Principal component 1 (PC1) clearly
- 1060 separates the cluster of mostly Romanian cases that are enriched with AA signatures, often
- 1061 at high mutation burdens. Principal component 3 (PC3) identifies a cluster of mostly
- 1062 Japanese cases, enriched with signature SBS12.
- 1063

1064 Extended Data Fig 3: Attribution of signatures SBS40a, SBS40b, and SBS40c in a pan-1065 cancer cohort.

Attribution of signatures SBS40a, SBS40b, and SBS40c in a pan-cancer cohort, showing a widespread distribution for SBS40a whilst SBS40b and SBS40c are only seen consistently in clear cell renal cell carcinomas (ccRCC). The size of each dot represents the proportion of samples of each tumor type where the signature is present. The color of each dot represents the average mutation burden.

1071

1072 Extended Data Fig. 4: Doublet-base substitution signatures operative in clear cell 1073 renal cell carcinomas.

1074 (a) Tumour mutation burden (TMB) plot showing the frequency and mutations per Mb for each of the decomposed DBS signatures. (b) Average relative attribution for doublet-base 1075 substitution (DBS) signatures across countries. Signatures contributing less than 5% on 1076 1077 average are grouped in the 'Other' category, apart from signature DBS D. Category named 1078 '<95% confidence' accounts for the proportion of mutation burden which could not be 1079 assigned to any signature with confidence level of at least 95%. (c) Decomposed DBS 1080 signatures, including reference COSMIC signatures as well as de novo signatures not 1081 decomposed into COSMIC reference signatures.

1082

1083 Extended Data Fig. 5: Small insertions and deletion signatures operative in clear cell 1084 renal cell carcinomas.

(a) Tumour mutation burden (TMB) plot showing the frequency and mutations per Mb for
each of the decomposed ID signatures. (b) Average relative attribution for small insertion and
deletion (ID) signatures across countries. Signatures contributing less than 5% on average
are grouped in the 'Others' category, apart from signature ID_C. Category named '<95%
confidence' accounts for the proportion of mutation burden which could not be assigned to
any signature with confidence level of at least 95%. (c) Decomposed ID signatures, including

1091 reference COSMIC signatures as well as *de novo* signatures not decomposed into COSMIC
1092 reference signatures.

1093

1094 Extended Data Fig. 6: Correlation amongst signatures SBS22a, SBS22b, DBS_D, ID_C.
 1095

Extended Data Table 1: Presence of signatures SBS22a, SBS22b, DBS_D, ID_C across
 countries.

1098

1099 Extended Data Fig. 7: Single base substitution signatures showing significant

1100 differences in attributed mutation burden between countries.

1101 Signatures SBS40a (a) and SBS40b (b) were more prevalent in high-incidence regions of

1102 Czech Republic and Lithuania. Signatures SBS22a (c) and SBS22b (d) were enriched in

1103 Romania and Serbia. SBS1 (e), SBS5 (f) and SBS4 (g) showed moderate differences across

1104 countries. Signature SBS12 (h) is highly prevalent in Japan. Five SBS1 hypermutators above

1105 mutation burden of 1000 were removed for clarity. Box and whiskers plots are in the style of

1106 Tukey. The line within the box is plotted at the median while the upper and lower ends are

indicated 25th and 75th percentiles. Whiskers show 1.5*IQR (interquartile range) and values

1108 outside it are shown as individual data points.

1109

1110 Extended Data Fig. 8: Association of mutational signatures with incidence of renal

1111 cancer.

1112 Number of mutations attributed to signatures (a) SBS40a, (b) ID5 and (c) ID8 against age-

1113 standardized incidence rate (ASR) of kidney cancer in each of the eleven countries

1114 represented in the cohort. Error bars represent standard errors of the mean. The p-values

shown are for the ASR variable in linear regressions across all cases, adjusted for sex andage of diagnosis.

. . . _

1117

1118

1119 Extended Data Fig. 9: Association of mutation burden with incidence of renal cancer.

1120 Association of age-standardized rates (ASR) of kidney cancer incidence with SBS (a), DBS

- 1121 (b) and ID (c) mutation burdens across countries. Error bars represent standard errors of the
- 1122 mean. The p-values shown are for the ASR variable in linear regressions across all cases,
- adjusted for sex and age of diagnosis.
- 1124

1125 **Extended Data Fig. 10: Evolutionary analysis of mutational signatures in ccRCC.**

1126 Comparison of mutational signatures between clonal and subclonal mutations. Lines show

the change in relative activity between the clonal mutations (main) and subclonal mutations

(sub) within a sample. Blue and red lines represent an activity change of more than 6% (blue

indicates higher in the clonal mutations; red indicates higher in the subclonal mutations). Bar

1130 plots show the distribution of activities in samples where the signature was present in the

1131 clonal and/or subclonal mutations; this number is represented in the title of each plot as

1132 X/223 for each signature. Black bars indicate one standard deviation away from the mean.

1133 Significance was assessed using a two-sided Wilcoxon signed-rank test, and q-values were

1134 generated using the Benjamini-Hochberg Procedure.

Fig.1



All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization / International Agency for Research on Cancer concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate borderlines for which there may not yet be full agreement.

Data source: GLOBOCAN 2020 Map production: IARC (http://gco.iarc.fr/today) World Health Organization © International Agency for Research on Cancer 2020 All rights reserved

Table 1

Country (ASR/100.000)		Brazil (4.5)	Canada (10.4)	Czechia (14.4)	Japan (7.6)	Lithuania (14.5)	Poland (8.1)	Romania (7.7)	Russia (10.3)	Serbia (7.4)	Thailand (1.8)	UK (10.3)	Total (4.6)
Number of cases		96	73	259	36	16	13	64	216	69	5	115	962
Sex	Female	44	22	93	8	9	5	25	98	30	4	42	380
	Male	52	51	166	28	7	8	39	118	39	1	73	582
	0-45	15	6	27	3	1	2	6	43	16	0	6	125
	45-55	20	17	51	5	0	6	10	44	11	0	22	186
Age at diagnosis	55-65	30	17	77	8	9	1	20	91	27	2	41	323
(years)	65-75	24	27	72	13	4	4	20	32	9	2	31	238
	75+	7	6	32	7	2	0	8	6	6	1	15	90
	1999-2005			93			13	14	18				138
Year of	2005-2010			111				19	70	1		31	232
recruitment	2010-2015		9	55	28			31	116	68		41	348
	2015-2020	96	64		8	16			12		5	43	244
	1	28	3	123	24	6	0	33	94	32		53	396
	II	2	0	42	1	0	6	12	24	4		8	99
Stage	III	16	23	46	6	5	5	18	65	26		38	248
	IV	7	10	38	5	2	2	1	33	7		16	121
	Missing	43	37	10		3					5		98
	<20	3	2	5	2	0	2	2	9	8	0	6	39
	20-25	21	10	100	25	2	3	17	84	28	3	23	316
Body mass index	25-30	35	24	85	7	6	6	30	40	20	1	45	299
	>30	37	37	69	2	8	2	14	83	13	1	41	307
	Missing							1					1
	No	45	28	129	16	5	9	39	125	28	2	58	484
Hypertension	Yes	51	44	130	20	10	4	24	91	41	3	56	474
	Missing		1			1		1				1	4
	No	76	55	130	29	9		45	186	61	3	95	689
Diabetes	Yes	20	16	36	((4	12	8	2	20	132
-	Missing		2	93			13	15	18				141
Family history of	No	90	42	165	35	16		54	192	67	5	102	726
CCRCC	Yes	5	4	22	1	0	10	1	6	2	0	3	43
	Missing	1	27	72			13	9	18	10		10	193
-	Current smoker	23	21	66	9	4	6	11	52	18	1	28	239
l obacco status	Ex-smoker	21	30	62	15	3	3	15	27	15	0	44	235
	Never	52	22	131	11	9	4	37	137	36	4	43	486
	iviissing	07	4.0	0.4	1	4.0	F 4	1	4.5	4.0		0.0	2
	Mean	0.7	1.6	3.4		1.3	5.4	1.3	1.5	1.3	2.2	3.3	2.2
PFOA (ng/mL)	(st. dev.)	(0.5)	(1.1)	(2.1)		(0.6)	(4.1)	(0.9)	(1.4)	(0.6)	(2.2)	(1.7)	(1.9)





Fig. 3











С







T>A





Extended Data Fig. 1.





С



Extended Data Fig. 2.





Extended Data Fig. 4.



С



Extended Data Fig. 5.





Extended Data Fig. 6.



Extended Data Table 1.

Country	N cases	SBS22a (%)	SBS22b (%)	DBS_D (%)	ID_C (%)	SBS22a or SBS22b (%)	Any (%)
Romania	64	45 (70.3)	48 (75.0)	42 (65.6)	13 (20.3)	53 (82.8)	54 (84.4)
Serbia	69	16 (23.2)	33 (47.8)	11 (15.9)	3 (4.3)	35 (50.7)	36 (52.2)
Thailand	5	3 (60.0)	3 (60.0)	0 (0.0)	0 (0.0)	4 (80.0)	4 (80.0)
Brazil	96	3 (3.1)	3 (3.1)	1 (1.0)	0 (0.0)	3 (3.1)	3 (3.1)
Canada	73	2 (2.7)	0 (0.0)	2 (2.7)	1 (1.4)	2 (2.7)	3 (4.1)
Czechia	259	1 (0.4)	5 (1.9)	32 (12.4)	0 (0.0)	6 (2.3)	37 (14.3)
UK	115	1 (0.9)	0 (0.0)	31 (27.0)	0 (0.0)	1 (0.9)	31 (27.0)
Russia	216	0 (0.0)	1 (0.5)	26 (12.0)	0 (0.0)	1 (0.5)	27 (12.5)
Poland	13	0 (0.0)	0 (0.0)	1 (7.7)	0 (0.0)	0 (0.0)	1 (7.7)
Lithuania	16	0 (0.0)	1 (6.2)	1 (6.2)	0 (0.0)	1 (6.2)	2 (12.5)
Japan	36	0 (0.0)	1 (2.8)	1 (2.8)	0 (0.0)	1 (2.8)	1 (2.8)

Extended Data Fig. 7.



Extended Data Fig. 8.







Extended Data Fig. 9.

а ASR/SBS burden association across countries







ASR/DBS burden association across countries

Extended Data Fig. 10.

